BioMark’s Health Canada Submission Update

Vancouver, British Columbia – (February 21st, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to provide an update on its Health Canada submission progress following data analysis on its clinical trial activities.

Listed below are new accomplishments over the past 2 weeks:

  1.  BioMark’s regulatory team at St. Boniface Hospital Research Centre and the assigned biostatistician have completed detailed data analysis and tabulation on clinical trials based in Canada and Bangladesh.
  2. A comprehensive medical follow up report of the outliers in both in Canada and Bangladesh has been reviewed by Dr. Andrew Maksymiuk, the Principal Investigator at CancerCare Manitoba along with our regulatory team members from St. Boniface Hospital Research Centre. Initial assessment report of the outliers demonstrates BioMark SSAT1 technology can provide physicians an economical diagnostic tool to effectively pre-screen patients for either more expensive CT screening or more invasive biopsy procedure. (Outliers are subjects who were considered healthy but exhibited higher than expected Acetyl Amantadine concentrations). An ongoing follow up will serve as part of our surveillance and strengthen the clinical applicability of our data.
  3. Compilation of the package to be filed with Health Canada has begun and a team has been assembled to accelerate the submission.

Next Steps
News will be released as soon as the submission package is completed in the next couple of weeks.

News Release – BIOMARK’s Health Canada Submission Update

Share this post:
Share on facebook
Share on twitter
Share on linkedin
Share on email
Categories
Archives

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
CSE: BUX
OTC: BMKDF
FSE: 20B
Investors

Related articles ...

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.